Open Access
Open access
BioMed Research International, volume 2015, pages 1-21

Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer

Kampan Nirmala Chandralega 1, 2
Madondo Mutsa Tatenda 1
McNally Orla M. 2, 3
Quinn Michael 2, 3
Plebanski Magdalena 1
1
 
Department of Immunology, Monash University, Level 6, The Alfred, Commercial Road, Melbourne, VIC 3181, Australia
2
 
Gynaeoncology Unit, Royal Women’s Hospital, 20 Flemington Road, Parkville, Melbourne, VIC 3052, Australia
3
 
Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC 3052, Australia
Publication typeJournal Article
Publication date2015-01-26
Quartile SCImago
Q2
Quartile WOS
Impact factor
ISSN23146133, 23146141
PubMed ID:  26137480
General Biochemistry, Genetics and Molecular Biology
General Medicine
General Immunology and Microbiology
Abstract
Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.

Citations by journals

2
4
6
8
10
12
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 12, 5.94%
International Journal of Molecular Sciences
12 publications, 5.94%
Molecules
Molecules, 8, 3.96%
Molecules
8 publications, 3.96%
Frontiers in Pharmacology
Frontiers in Pharmacology, 5, 2.48%
Frontiers in Pharmacology
5 publications, 2.48%
Cancers
Cancers, 5, 2.48%
Cancers
5 publications, 2.48%
Biomedicines
Biomedicines, 5, 2.48%
Biomedicines
5 publications, 2.48%
Scientific Reports
Scientific Reports, 5, 2.48%
Scientific Reports
5 publications, 2.48%
Biomedicine and Pharmacotherapy
Biomedicine and Pharmacotherapy, 3, 1.49%
Biomedicine and Pharmacotherapy
3 publications, 1.49%
Anti-Cancer Agents in Medicinal Chemistry
Anti-Cancer Agents in Medicinal Chemistry, 2, 0.99%
Anti-Cancer Agents in Medicinal Chemistry
2 publications, 0.99%
Tumor Biology
Tumor Biology, 2, 0.99%
Tumor Biology
2 publications, 0.99%
Medicine (United States)
Medicine (United States), 2, 0.99%
Medicine (United States)
2 publications, 0.99%
Pharmaceutics
Pharmaceutics, 2, 0.99%
Pharmaceutics
2 publications, 0.99%
Metabolites
Metabolites, 2, 0.99%
Metabolites
2 publications, 0.99%
Current Pharmacology Reports
Current Pharmacology Reports, 2, 0.99%
Current Pharmacology Reports
2 publications, 0.99%
European Journal of Medical Research
European Journal of Medical Research, 2, 0.99%
European Journal of Medical Research
2 publications, 0.99%
Abdominal Radiology
Abdominal Radiology, 2, 0.99%
Abdominal Radiology
2 publications, 0.99%
BMC Cancer
BMC Cancer, 2, 0.99%
BMC Cancer
2 publications, 0.99%
PLoS ONE
PLoS ONE, 2, 0.99%
PLoS ONE
2 publications, 0.99%
Bioorganic Chemistry
Bioorganic Chemistry, 2, 0.99%
Bioorganic Chemistry
2 publications, 0.99%
Gynecologic Oncology
Gynecologic Oncology, 2, 0.99%
Gynecologic Oncology
2 publications, 0.99%
Drug Delivery
Drug Delivery, 2, 0.99%
Drug Delivery
2 publications, 0.99%
Expert Opinion on Drug Delivery
Expert Opinion on Drug Delivery, 2, 0.99%
Expert Opinion on Drug Delivery
2 publications, 0.99%
Oxidative Medicine and Cellular Longevity
Oxidative Medicine and Cellular Longevity, 2, 0.99%
Oxidative Medicine and Cellular Longevity
2 publications, 0.99%
BioMed Research International
BioMed Research International, 2, 0.99%
BioMed Research International
2 publications, 0.99%
Annales Pharmaceutiques Francaises
Annales Pharmaceutiques Francaises, 1, 0.5%
Annales Pharmaceutiques Francaises
1 publication, 0.5%
Pharmaceutical Chemistry Journal
Pharmaceutical Chemistry Journal, 1, 0.5%
Pharmaceutical Chemistry Journal
1 publication, 0.5%
JAMA Oncology
JAMA Oncology, 1, 0.5%
JAMA Oncology
1 publication, 0.5%
Current Pharmaceutical Design
Current Pharmaceutical Design, 1, 0.5%
Current Pharmaceutical Design
1 publication, 0.5%
Nanomedicine
Nanomedicine, 1, 0.5%
Nanomedicine
1 publication, 0.5%
Cancer Biotherapy and Radiopharmaceuticals
Cancer Biotherapy and Radiopharmaceuticals, 1, 0.5%
Cancer Biotherapy and Radiopharmaceuticals
1 publication, 0.5%
2
4
6
8
10
12

Citations by publishers

5
10
15
20
25
30
35
40
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 39, 19.31%
Multidisciplinary Digital Publishing Institute (MDPI)
39 publications, 19.31%
Springer Nature
Springer Nature, 36, 17.82%
Springer Nature
36 publications, 17.82%
Elsevier
Elsevier, 34, 16.83%
Elsevier
34 publications, 16.83%
Taylor & Francis
Taylor & Francis, 12, 5.94%
Taylor & Francis
12 publications, 5.94%
Wiley
Wiley, 11, 5.45%
Wiley
11 publications, 5.45%
Frontiers Media S.A.
Frontiers Media S.A., 6, 2.97%
Frontiers Media S.A.
6 publications, 2.97%
Bentham Science
Bentham Science, 5, 2.48%
Bentham Science
5 publications, 2.48%
SAGE
SAGE, 5, 2.48%
SAGE
5 publications, 2.48%
Hindawi Limited
Hindawi Limited, 5, 2.48%
Hindawi Limited
5 publications, 2.48%
American Chemical Society (ACS)
American Chemical Society (ACS), 4, 1.98%
American Chemical Society (ACS)
4 publications, 1.98%
Spandidos Publications
Spandidos Publications, 3, 1.49%
Spandidos Publications
3 publications, 1.49%
Wolters Kluwer Health
Wolters Kluwer Health, 3, 1.49%
Wolters Kluwer Health
3 publications, 1.49%
Public Library of Science (PLoS)
Public Library of Science (PLoS), 3, 1.49%
Public Library of Science (PLoS)
3 publications, 1.49%
Future Medicine
Future Medicine, 2, 0.99%
Future Medicine
2 publications, 0.99%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 2, 0.99%
Royal Society of Chemistry (RSC)
2 publications, 0.99%
Dove Medical Press
Dove Medical Press, 2, 0.99%
Dove Medical Press
2 publications, 0.99%
AME Publishing Company
AME Publishing Company, 2, 0.99%
AME Publishing Company
2 publications, 0.99%
American Medical Association (AMA)
American Medical Association (AMA), 1, 0.5%
American Medical Association (AMA)
1 publication, 0.5%
Mary Ann Liebert
Mary Ann Liebert, 1, 0.5%
Mary Ann Liebert
1 publication, 0.5%
Pharmaceutical Society of Japan
Pharmaceutical Society of Japan, 1, 0.5%
Pharmaceutical Society of Japan
1 publication, 0.5%
The Royal Society
The Royal Society, 1, 0.5%
The Royal Society
1 publication, 0.5%
Cognizant Communication Corporation, 1, 0.5%
Cognizant Communication Corporation
1 publication, 0.5%
Korean Society for Biotechnology and Bioengineering, 1, 0.5%
Korean Society for Biotechnology and Bioengineering
1 publication, 0.5%
Neoplasia Press, 1, 0.5%
Neoplasia Press
1 publication, 0.5%
American Society for Biochemistry and Molecular Biology
American Society for Biochemistry and Molecular Biology, 1, 0.5%
American Society for Biochemistry and Molecular Biology
1 publication, 0.5%
Pleiades Publishing
Pleiades Publishing, 1, 0.5%
Pleiades Publishing
1 publication, 0.5%
Oxford University Press
Oxford University Press, 1, 0.5%
Oxford University Press
1 publication, 0.5%
American Association for Cancer Research (AACR)
American Association for Cancer Research (AACR), 1, 0.5%
American Association for Cancer Research (AACR)
1 publication, 0.5%
eLife Sciences Publications
eLife Sciences Publications, 1, 0.5%
eLife Sciences Publications
1 publication, 0.5%
5
10
15
20
25
30
35
40
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Kampan N. C. et al. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer // BioMed Research International. 2015. Vol. 2015. pp. 1-21.
GOST all authors (up to 50) Copy
Kampan N. C., Madondo M. T., McNally O. M., Quinn M., Plebanski M. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer // BioMed Research International. 2015. Vol. 2015. pp. 1-21.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1155/2015/413076
UR - https://doi.org/10.1155%2F2015%2F413076
TI - Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
T2 - BioMed Research International
AU - Kampan, Nirmala Chandralega
AU - Madondo, Mutsa Tatenda
AU - McNally, Orla M.
AU - Quinn, Michael
AU - Plebanski, Magdalena
PY - 2015
DA - 2015/01/26 00:00:00
PB - Hindawi Limited
SP - 1-21
VL - 2015
PMID - 26137480
SN - 2314-6133
SN - 2314-6141
ER -
BibTex
Cite this
BibTex Copy
@article{2015_Kampan,
author = {Nirmala Chandralega Kampan and Mutsa Tatenda Madondo and Orla M. McNally and Michael Quinn and Magdalena Plebanski},
title = {Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer},
journal = {BioMed Research International},
year = {2015},
volume = {2015},
publisher = {Hindawi Limited},
month = {jan},
url = {https://doi.org/10.1155%2F2015%2F413076},
pages = {1--21},
doi = {10.1155/2015/413076}
}
Found error?